1. Controlling BMP growth factor bioavailability: The extracellular matrix as multi skilled platform
- Author
-
Ariane G. Furlan, Chara E.S. Spanou, Laura-Marie A. Zimmermann, Annkatrin Correns, and Gerhard Sengle
- Subjects
Connective Tissue Disorder ,Extracellular Matrix Proteins ,Chemistry ,Growth factor ,medicine.medical_treatment ,Connective tissue ,Context (language use) ,Cell Biology ,Bone morphogenetic protein ,Cell biology ,Extracellular Matrix ,Extracellular matrix ,medicine.anatomical_structure ,Transforming Growth Factor beta ,Bone Morphogenetic Proteins ,medicine ,Intercellular Signaling Peptides and Proteins ,Receptor ,Fibrillin - Abstract
Bone morphogenetic proteins (BMPs) belong to the TGF-β superfamily of signaling ligands which comprise a family of pluripotent cytokines regulating a multitude of cellular events. Although BMPs were originally discovered as potent factors extractable from bone matrix that are capable to induce ectopic bone formation in soft tissues, their mode of action has been mostly studied as soluble ligands in absence of the physiologically relevant cellular microenvironment. This micro milieu is defined by supramolecular networks of extracellular matrix (ECM) proteins that specifically target BMP ligands, present them to their cellular receptors, and allow their controlled release. Here we focus on functional interactions and mechanisms that were described to control BMP bioavailability in a spatio-temporal manner within the respective tissue context. Structural disturbance of the ECM architecture due to mutations in ECM proteins leads to dysregulated BMP signaling as underlying cause for connective tissue disease pathways. We will provide an overview about current mechanistic concepts of how aberrant BMP signaling drives connective tissue destruction in inherited and chronic diseases.
- Published
- 2021